當地時間5月7日，世界衛生組織宣布，由中國醫藥集團北京生物制品研究所研發的新冠滅活疫苗正式通過世衛組織緊急使用認證。

"This afternoon, the WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," said WHO Director General Dr. Tedros Adhanom Ghebreyesus at a press briefing.
世衛組織總干事譚德塞在新聞發布會上說，世衛組織當天下午為中國國藥新冠疫苗頒發了緊急使用認證，使其成為第6種獲得世衛組織安全性、有效性和質量驗證的新冠疫苗。

"This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine," he said.
這擴大了世衛組織主導的“新冠肺炎疫苗實施計劃”（COVAX）組合的疫苗庫名單，并有助于各國加快對新冠疫苗的監管審批以及進口和接種疫苗。

【知識點】

2020年10月8日，中國同全球疫苗免疫聯盟簽署協議，正式加入“新冠肺炎疫苗實施計劃（COVAX）”。這是中國秉持人類衛生健康共同體理念（uphold the concept of a shared community of health for all）、履行自身承諾推動疫苗成為全球公共產品（turn COVID-19 vaccines into a global public good）的一個重要舉措。

“新冠肺炎疫苗實施計劃”由世界衛生組織和全球疫苗免疫聯盟、流行病防范創新聯盟共同牽頭成立，擬于2021年底前向全球提供20億劑新冠肺炎疫苗（the initial aim is to have 2 billion doses available by the end of 2021），供應給“自費經濟體（higher-income self-financing countries）”和“受資助經濟體（lower-income funded nations）”。包括我國在內的“自費經濟體”需向該計劃承諾為本經濟體一定比例人口購買疫苗并繳納預付款，而“受資助經濟體”無須繳納預付款，同時享受該計劃補貼。

世衛組織負責獲得藥品和衛生產品的助理總干事瑪麗安熱拉·西芒當天在一份聲明中表示，

The addition of the Sinopharm vaccine has "the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk".
將中國國藥新冠疫苗納入世衛組織緊急使用清單“有助于尋求保護衛生工作者和高危人群的國家加速獲得新冠疫苗”。

The jab produced by the Beijing Bio-Institute of Biological Products Co. Ltd., a subsidiary of the China National Biotec Group, is an inactivated vaccine with easy storage requirements, which makes it highly suitable for use in low-resource settings.
中國醫藥集團北京生物制品研究所研發的新冠滅活疫苗易于儲存，使其非常適用于資源匱乏的環境。

It is also the first vaccine that will carry a vial monitor, a small sticker on the vials that changes color if the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
它也是第一款攜帶疫苗瓶監測器的疫苗，疫苗瓶上的小標簽會因疫苗受熱而改變顏色，便于衛生工作者判斷疫苗是否安全可用。

According to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE), the Sinopharm vaccine is recommended for use in adults 18 years and older in a two-dose schedule with a spacing of three to four weeks.
根據世衛組織免疫戰略咨詢專家組的意見，世衛組織建議將中國國藥新冠疫苗用于18歲及以上成年人，采用兩劑注射、間隔時間為3至4周。

The WHO is not recommending an upper age limit for the Sinopharm vaccine, because reviewed data have suggested that the vaccine is likely to have a protective effect in older persons, according to the WHO press release.
世衛組織不建議對中國國藥新冠疫苗設置使用年齡上限，因為評估數據顯示，該疫苗對老年人可能也有保護作用。

The WHO had previously listed the COVID-19 vaccine developed by Pfizer/BioNTech, two versions of the AstraZeneca/Oxford vaccine, the Janssen vaccine and the Moderna vaccine for emergency use.
此前，世衛組織已向5種新冠疫苗頒發緊急使用認證，分別是美國輝瑞制藥有限公司和德國生物新技術公司聯合研發的新冠疫苗、英國阿斯利康制藥公司和牛津大學聯合研發的兩個版本阿斯利康疫苗、美國強生公司旗下楊森制藥公司研發的新冠疫苗以及美國莫德納公司研發的新冠疫苗。

【相關詞匯】

藥品和疫苗研發
drug and vaccine development

有效性和安全性研究
safety and efficacy research

人類衛生健康共同體
a global community of health for all

疫苗聯合研發
joint research and development of vaccines

全球公共產品
global public good

參考來源：新華網

（中國日報網英語點津 Helen）